We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$421M
AUM Growth
+$85.4M
Cap. Flow
+$55.9M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.23%
Holding
96
New
22
Increased
24
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$11.6M
2
RVMD icon
Revolution Medicines
RVMD
+$5.77M
3
PLX icon
Protalix BioTherapeutics
PLX
+$5.61M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.51M
5
ACET icon
Adicet Bio
ACET
+$4.41M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.07M
2
STIM icon
Neuronetics
STIM
+$2.91M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$2.9M
4
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.46M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Miscellaneous 2.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$91.9M 21.81%
13,680,554
– –
FATE icon
2
Fate Therapeutics
FATE
$291M
$25.9M 6.15%
314,360
-20,000
-6% -$1.92M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$20.2M 4.8%
207,911
+1,000
+0.5% +$99.8K
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$15M 3.57%
587,756
– –
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$13.6M 3.22%
181,306
– –
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$11.5M 2.72%
181,467
+120,000
+195% +$5.51M
NRIX icon
7
Nurix Therapeutics
NRIX
$2.72B
$9.52M 2.26%
+306,320
New +$11.6M
ATRC icon
8
AtriCure
ATRC
$2.47B
$8.42M 2%
128,529
-4,700
-4% -$289K
AFMD
9
DELISTED
Affimed
AFMD
$7.83M 1.86%
98,986
+11,550
+13% +$750K
IDYA icon
10
IDEAYA Biosciences
IDYA
$3.87B
$7.79M 1.85%
331,661
– –
DXCM icon
11
DexCom
DXCM
$34.3B
$7.6M 1.8%
84,552
– –
XENE icon
12
Xenon Pharmaceuticals
XENE
$5.81B
$7.28M 1.73%
406,535
+60,000
+17% +$1.02M
PRQR icon
13
ProQR Therapeutics
PRQR
$323M
$7.27M 1.73%
1,100,000
-137,400
-11% -$702K
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.7B
$7.16M 1.7%
73,655
-18,553
-20% -$1.95M
RVMD icon
15
Revolution Medicines
RVMD
$44.6B
$6.94M 1.65%
151,231
+128,731
+572% +$5.77M
BHVN
16
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.4M 1.52%
93,600
+11,500
+14% +$930K
IBB icon
17
iShares Biotechnology ETF
IBB
$10.5B
$6.08M 1.44%
40,400
-7,000
-15% -$1.11M
LKFT
18
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$5.79M 1.37%
75,175
-5,200
-6% -$479K
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.77M 1.37%
48,000
+31,332
+188% +$3.55M
CSII
20
DELISTED
Cardiovascular Systems, Inc.
CSII
$5.74M 1.36%
149,700
-1,500
-1% -$63.8K
TVRD
21
Tvardi Therapeutics
TVRD
$24.3M
$5.68M 1.35%
7,262
– –
PLX icon
22
Protalix BioTherapeutics
PLX
$205M
$5.37M 1.28%
+1,204,825
New +$5.61M
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.32M 1.26%
76,715
-100
-0.1% -$7.7K
ACET icon
24
Adicet Bio
ACET
$84.8M
$5.04M 1.2%
24,067
+19,218
+396% +$4.41M
AERI
25
DELISTED
Aerie Pharmaceuticals
AERI
$4.93M 1.17%
275,840
-12,600
-4% -$218K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, DAFNA Capital Management held 96 positions worth $421M, up 25% from $336M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $55.9M of net new capital in Q1 2021, opening 22 new positions and adding to 24 existing holdings. Its largest new stake was Nurix Therapeutics: 306,320 shares worth $9.52M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Neuronetics, an estimated $2.91M trimmed.

  • DAFNA Capital Management's largest Q1 2021 buy was Nurix Therapeutics: 306,320 shares worth $9.52M.
  • DAFNA Capital Management added most to Revolution Medicines in Q1 2021, an estimated $5.77M increase.
  • DAFNA Capital Management's biggest Q1 2021 reduction was Neuronetics, cutting an estimated $2.91M.
  • DAFNA Capital Management fully exited Filana Therapeutics in Q1 2021, selling an estimated $3.07M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $421M portfolio in Q1 2021.
  • DAFNA Capital Management opened 22 new positions and closed 7 in Q1 2021.
  • DAFNA Capital Management's portfolio value rose 25% quarter-over-quarter to $421M.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.